- Korea’s National Growth Fund (₩150 trillion over 5 years) targets 12 strategic sectors including biotech, AI, and semiconductors.
- The fund sold out its initial offering period, signaling strong retail demand and triggering biotech/KOSDAQ momentum.
- KOSPI has surged past 8,000 on semiconductor dominance, but the rally is dangerously narrow — Samsung and Hynix alone represent ~57% of KOSPI market cap.
- A late-June single-day crash saw foreigners sell ₩6.2 trillion and institutions ₩5.6 trillion, exposing structural fragility beneath the bull narrative.
- The KOSDAQ promotion/relegation system launching in October poses a direct threat to loss-making biotech names currently riding fund euphoria.
The biotech bounce today is rotation, not conviction. Semis pulled back, money moved. That’s it.
Agree on the mechanism. But the fund itself is real — ₩150 trillion, 5-year closed structure, tax benefits.
Real money, yes. But ask who is buying. Income under ₩50M/year — retail, not institutions.
Retail capital chasing policy narrative. We’ve seen this movie.
A fund selling out in two weeks proves demand, not fundamentals. Those are different things.
Exactly. NatureCell hit limit-up on stem cell hype the same week the fund launched. Coincidence?
That’s the pattern. Policy signal arrives, retail front-runs, momentum players pile in.
And then what? KOSDAQ biotech faces relegation criteria in October — market cap AND profitability.
Most of these names are loss-making. By definition.
Right. Biotech “eats dreams,” as they say. Years of losses, trillion-won valuations on pipeline hope.
So the fund creates the rally, the relegation rule potentially destroys it. Six-month window.
Policy giveth, policy taketh. And retail is always last to know.
Let’s not overstate the fund’s direct impact though. It’s a private equity fund-of-funds structure.
Correct. It doesn’t buy KOSDAQ stocks directly. The market is pricing in anticipation of downstream flows.
Which is exactly how you build a policy-driven bubble. The expectation does the work before the money arrives.
Meanwhile Samsung plus Hynix is 57% of KOSPI market cap. The entire market structure is broken.
And the government approved leveraged ETFs on those two names. Into that concentration. Remarkable.
Foreign rebalancing alone wiped the market in a single session — ₩6.2T foreign, ₩5.6T institutional.
Passive funds mechanically selling into a rally they helped create. Nobody calls that a catalyst.
So what’s the actual bull case for biotech here? Walk me through it honestly.
Lowest valuations in years, policy tailwind, and semis finally taking a breath. That’s the whole thesis — and it’s thin.
If AI capex narrative holds, semis stay dominant and biotech stays a sideshow regardless of the fund.
Structurally I’d want to see a named deal — a licensing out, an FDA milestone — not a fund announcement.
Until then, this is liquidity seeking narrative, not narrative supported by fundamentals.
Korea’s National Growth Fund is a genuine structural commitment — ₩150 trillion earmarked for strategic industries over five years, with real tax incentives and closed-end discipline. But the biotech rally it has catalyzed so far is almost entirely anticipatory: retail capital front-running a policy signal before a single won of fund money has materially reached KOSDAQ-listed biotechs. The deeper problem is structural. A market where two semiconductor names command 57% of index weight, where leveraged ETFs on those same names have just been approved, and where a single session of foreign rebalancing can produce historically extreme drawdowns, is not a market that needs more concentrated enthusiasm — it needs diversification of a different kind. The October KOSDAQ relegation criteria will be the real test: loss-making biotech names now trading on fund euphoria face a hard profitability screen that the rally has done nothing to address. For investors, the honest framing is this — the Growth Fund may prove to be a multi-year structural catalyst, but the current biotech momentum is running well ahead of any mechanism that would justify it.
Related reading: Korea ETF Delisting: Who Pays for Tracking Failure?